Clinical Report: FDA approves oral dermatomyositis therapy
Overview
The FDA has approved brepocitinib (Lisraya) as the first oral treatment for dermatomyositis. This approval follows a phase 3 trial demonstrating improved Total Improvement Scores in patients receiving brepocitinib compared to placebo.
Background
Dermatomyositis is a rare autoimmune disease characterized by muscle weakness and skin rashes, leading to significant morbidity.
Brepocitinib 30 mg showed higher Total Improvement Scores at week 52 compared to placebo.
Key Findings
Brepocitinib is the first FDA-approved oral therapy for dermatomyositis.
The phase 3 trial involved 241 adults and assessed Total Improvement Scores over 52 weeks.
Participants receiving brepocitinib 30 mg experienced greater improvements in physical function and skin disease activity.
Adverse reactions included upper respiratory tract infections and headaches, with 6% discontinuation in the 30 mg group.
Brepocitinib carries warnings for serious infections and increased all-cause mortality.
Clinical Implications
Healthcare providers should consider brepocitinib as a treatment option for adults with dermatomyositis, particularly for those who have not responded to other therapies. Monitoring for adverse effects, especially serious infections, is essential during treatment.
Conclusion
The approval of brepocitinib represents a significant advancement in the management of dermatomyositis, offering a new oral treatment option for affected patients.
